To further substantiate the clinical significance of the m6A-associated lncRNAs in leukemia, we also examined the expression of LN989, PROX1-AS1, SENCR, LN892, and KIF25-AS1 in AML patients, who received nilotinib twice daily after induction and consolidation chemotherapy [37]. Here, PROX1 is linked to leukemia.